Robeco Institutional Asset Management B.V. Buys 1,452,192 Shares of Dr. Reddy's Laboratories Ltd $RDY

Key Points

• Robeco Institutional Asset Management B.V. increased its holding in Dr. Reddy's Laboratories by 13.6%, acquiring an additional 1,452,192 shares to bring its total ownership to 12,163,428 shares.
• Several hedge funds also boosted their positions in Dr. Reddy's Laboratories, with Two Sigma Advisers LP increasing its stake by 254.8% during the 4th quarter, owning now 33,000 shares.
• Analysts have raised their ratings for Dr. Reddy's Laboratories, with HSBC upgrading the stock from "hold" to "strong-buy" and setting a new price target of $16.90.

Robeco Institutional Asset Management B.V. increased its stake in shares of Dr. Reddy's Laboratories Ltd (NYSE:RDY - Free Report) by 13.6% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 12,163,428 shares of the company's stock after buying an additional 1,452,192 shares during the quarter. Robeco Institutional Asset Management B.V. owned 1.46% of Dr. Reddy's Laboratories worth $182,816,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also modified their holdings of RDY. Two Sigma Advisers LP lifted its position in shares of Dr. Reddy's Laboratories by 254.8% during the 4th quarter. Two Sigma Advisers LP now owns 33,000 shares of the company's stock worth $521,000 after buying an additional 23,700 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in Dr. Reddy's Laboratories by 100.2% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 16,511 shares of the company's stock valued at $261,000 after purchasing an additional 8,262 shares in the last quarter. Wealth Enhancement Advisory Services LLC acquired a new stake in Dr. Reddy's Laboratories during the 4th quarter valued at $206,000. GAMMA Investing LLC increased its holdings in Dr. Reddy's Laboratories by 971.5% during the 1st quarter. GAMMA Investing LLC now owns 72,848 shares of the company's stock valued at $961,000 after purchasing an additional 66,049 shares in the last quarter. Finally, Foster Group Inc. increased its holdings in Dr. Reddy's Laboratories by 8.3% during the 1st quarter. Foster Group Inc. now owns 14,838 shares of the company's stock valued at $196,000 after purchasing an additional 1,134 shares in the last quarter. Institutional investors own 3.85% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on RDY. Hsbc Global Res raised Dr. Reddy's Laboratories from a "hold" rating to a "strong-buy" rating in a report on Thursday, June 5th. Zacks Research raised Dr. Reddy's Laboratories from a "strong sell" rating to a "hold" rating in a report on Friday, August 15th. Finally, HSBC raised Dr. Reddy's Laboratories from a "hold" rating to a "buy" rating and raised their price target for the company from $14.44 to $16.90 in a report on Thursday, June 5th. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat.com, Dr. Reddy's Laboratories has an average rating of "Moderate Buy" and a consensus target price of $16.95.

Dr. Reddy's Laboratories Stock Up 1.5%

NYSE RDY opened at $14.20 on Thursday. The stock has a fifty day moving average of $14.28 and a 200-day moving average of $14.25. The stock has a market capitalization of $11.85 billion, a P/E ratio of 21.51, a price-to-earnings-growth ratio of 5.65 and a beta of 0.40. Dr. Reddy's Laboratories Ltd has a 52 week low of $12.26 and a 52 week high of $16.17. The company has a debt-to-equity ratio of 0.01, a quick ratio of 1.36 and a current ratio of 1.89.

Dr. Reddy's Laboratories (NYSE:RDY - Get Free Report) last released its earnings results on Wednesday, July 23rd. The company reported $0.20 EPS for the quarter, beating the consensus estimate of $0.18 by $0.02. The company had revenue of $988.82 million during the quarter, compared to analysts' expectations of $88.27 billion. Dr. Reddy's Laboratories had a return on equity of 17.25% and a net margin of 16.99%. On average, equities research analysts forecast that Dr. Reddy's Laboratories Ltd will post 0.8 EPS for the current year.

Dr. Reddy's Laboratories Company Profile

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.